Drug Trial Radar · NCT05291286
BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients
Last checked: Nov 20, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Oct 17, 2022
Primary completion
Dec 20, 2024
Study completion Dec 20, 2024
Sponsor
- Lead sponsor
- Bexion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- CTI Clinical Trial and Consulting Services
- First posted
- Mar 22, 2022
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess pharmacokinetic (PK)/pharmacodynamic (PD) relationships and whether BXQ-350 may decrease the intensity and/or duration of chemotherapy induced peripheral neuropathy (CIPN) thereby improving quality of life (QoL) in cancer patients who have been exposed to oxaliplatin and/or taxane-based chemotherapy. This study includes two randomized, placebo controlled, blinded treatment cycles of BXQ-350/placebo, an optional open-label BXQ-350 treatment period, and an unblinded Post-Treatment Follow-up period.
Conditions
- Neuropathy;Peripheral
- Chemotherapy-induced Peripheral Neuropathy
Interventions
BXQ-350Drug
BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion
PlaceboOther
Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak Plasma Concentration (Cmax)Time frame: 6 months
- CeramideTime frame: 6 months
- S1P levelsTime frame: 6 months
- Cytokine levelsTime frame: 6 months
- Quality of Life (QoL)Time frame: 6 months
- Total Sensory NeuropathyTime frame: 6 months
- CIPN AssessmentTime frame: 6 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
CTI Clinical Research Center
Cincinnati, Ohio
The Ohio State Unviersity
Columbus, Ohio
Vanderbilt University Medical Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.